Table 2 The characteristics of meibomian gland structure and function of included patients
Variable | Total (N = 90 eyes) | Inactive group (N = 49 eyes) | Active group (N = 41 eyes) | P-value |
|---|---|---|---|---|
MOA | 1672.00 (1153.00 ~ 2444.75) | 1699.00 (1310.00 ~ 2694.00) | 1643.00 (1104.00 ~ 2170.00) | 0.630* |
MAD | 85.51 ± 35.35 | 93.59 ± 39.09 | 75.85 ± 27.78 | 0.028† |
MALD | 116.91 ± 28.99 | 119.31 ± 27.72 | 114.05 ± 30.53 | 0.267† |
MASD | 41.59(31.85 ~ 54.69) | 42.45(34.54 ~ 54.71) | 39.12(29.78 ~ 54.56) | 0.598* |
MAI | 0.012# | |||
0 | 1(1.11%) | 1(2.04%) | 0(0.00%) | |
1 | 53(58.89%) | 34(69.39%) | 19(46.34%) | |
2 | 32(35.56%) | 14(28.57%) | 18(43.90%) | |
3 | 4(4.44%) | 0(0.00%) | 4(9.76%) | |
MSR | < 0.001# | |||
0 | 1(1.11%) | 1(2.04%) | 0(0.00%) | |
1 | 49(54.44%) | 17(34.69%) | 32(78.05%) | |
2 | 32(35.56%) | 23(46.94%) | 9(21.95%) | |
3 | 8(8.89%) | 8(16.33%) | 0(0.00%) | |
AWI | < 0.001# | |||
0 | 12(13.33%) | 12(24.49%) | 0(0.00%) | |
1 | 44(48.89%) | 31(63.27%) | 13(31.71%) | |
2 | 22(24.44%) | 6(12.24%) | 16(39.02%) | |
3 | 12(13.33%) | 0(0.00%) | 12(29.27%) | |
API | < 0.001# | |||
0 | 10(11.11%) | 10(20.41%) | 0(0.00%) | |
1 | 37(41.11%) | 28(57.14%) | 9(21.95%) | |
2 | 31(34.44%) | 11(22.45%) | 20(48.78%) | |
3 | 12(13.33%) | 0(0.00%) | 12(29.27%) | |
MF | 0.005# | |||
0 | 25(27.78%) | 7(14.29%) | 18(43.90%) | |
1 | 56(62.22%) | 37(75.51%) | 19(46.34%) | |
2 | 9(10.00%) | 5(10.20%) | 4(9.76%) |